Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07018323 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 160 → 163 locationsv23
  2. Study sites: 158 to 160v22
  3. Trial sites expanded: 154 → 158 locationsv21
  4. Trial sites expanded: 149 → 154 locationsv20
  5. Trial sites expanded: 145 → 149 locationsv19
  6. Trial sites expanded: 136 → 145 locationsv18
  7. Trial sites expanded: 126 → 136 locationsv17
  8. Trial sites expanded: 120 → 126 locationsv16
  9. Trial sites expanded: 116 → 120 locationsv15
  10. Trial sites expanded: 112 → 116 locationsv14
  11. Study sites: 110 to 112v13
  12. Study sites: 104 to 110v12
  13. Study sites: 97 to 104v11
  14. Study sites: 90 to 97v10
  15. Study sites: 34 to 90
    • Eligibility criteria expanded, about 1 word
    v9
  16. Study sites: 27 to 34v8
  17. Study sites: 22 to 27v7
  18. Study sites: 10 to 22v6
  19. Study sites: 6 to 10v5
  20. Study sites: 5 to 6v4
  21. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 5
    • Start date changed from estimate of Jul 2025 to Jun 19, 2025
    v3
  22. Re-verified, no change to tracked fieldsv2
  23. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Trial Details
NCT Number NCT07018323
Lead Sponsor Immunovant Sciences GmbH
Conditions
(from sponsor)		 Graves' Disease
Related terms Graves Disease
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov